Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 28: Klinische Wirksamkeit - MicardisPlus Abb. 29: Telmisartan - HCTZ Abb. 30: Telmisartan - HCTZ Aktuelles Bild - Abb. 31: Telmisartan - HCTZ Abb. 32: Telmisartan - Losartan - HCTZ Abb. 33: Telmisartan - Losartan - HCTZ Abb. 34: Telmisartan - Valsartan - HCTZ Zum letzten Bild
Abbildung 31: Telmisartan - HCTZ
This was an 8-week study in 491 patients with mild-to-moderate hypertension who were non-responders (DBP 90 mmHg) in an open-label period of telmisartan 80 mg monotherapy.1 Patients were randomized to either continuation of monotherapy or fixed-dose combination with HCTZ 12.5 mg. After 8 weeks, mean DBP changes were -4.9 and -8.0 mmHg in the monotherapy and combination therapy groups, respectively (p<0.01). Mean SBP changes were -7.0 and -12.6 mmHg in the monotherapy and combination therapy groups, respectively (p<0.01). Most of the relative improvements with combination therapy occurred in the first 4 weeks. By endpoint, blood pressure was normalized (SBP/DBP <140/<90 mmHg) in 41.5% of patients on combination therapy and 26.1% of patients on monotherapy (P<0.05). 1. Lacourcière Y, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763–770.
 
Telmisartan - HCTZ
Vorheriges Bild Nächstes Bild   


Abbildung 31: Telmisartan - HCTZ
This was an 8-week study in 491 patients with mild-to-moderate hypertension who were non-responders (DBP 90 mmHg) in an open-label period of telmisartan 80 mg monotherapy.1 Patients were randomized to either continuation of monotherapy or fixed-dose combination with HCTZ 12.5 mg. After 8 weeks, mean DBP changes were -4.9 and -8.0 mmHg in the monotherapy and combination therapy groups, respectively (p<0.01). Mean SBP changes were -7.0 and -12.6 mmHg in the monotherapy and combination therapy groups, respectively (p<0.01). Most of the relative improvements with combination therapy occurred in the first 4 weeks. By endpoint, blood pressure was normalized (SBP/DBP <140/<90 mmHg) in 41.5% of patients on combination therapy and 26.1% of patients on monotherapy (P<0.05). 1. Lacourcière Y, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763–770.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung